Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

203
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
203
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

195
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
195
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

403
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
403
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

488
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
488
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

330
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
330
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

486
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
486

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

AI-driven diagnosis of mpox using deep learning models.

PloS one·2026
Same journal

The impact of transparency and imitation over complex networks in strategic classification.

PloS one·2026
Same journal

Edge-intelligent safelink-V2X: A low-latency cooperative framework for real-time vulnerable road user protection.

PloS one·2026
Same journal

Loss of Fmr1 reorganizes the multi-elemental composition across tissues in Fragile X Syndrome mice.

PloS one·2026
Same journal

Exploring the predictability of distributed lag nonlinear models using SARS-CoV-2 wastewater-based surveillance in multiple communities in Alberta, Canada.

PloS one·2026
Same journal

NLOS/LOS identification with LightGBM ensemble.

PloS one·2026

Related Experiment Video

Updated: Dec 23, 2025

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke
09:50

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke

Published on: February 12, 2015

11.5K

A Bayesian approach to discrete multiple outcome network meta-analysis.

Rebecca Graziani1,2,3, Sergio Venturini4,5

  • 1Department of Social and Political Sciences, Bocconi University, Milan, Italy.

Plos One
|April 29, 2020
PubMed
Summary
This summary is machine-generated.

This study introduces a novel Bayesian network meta-analysis method for multiple discrete outcomes using Gaussian copulas. The approach enhances evidence synthesis for complex health data, offering a new tool for researchers.

More Related Videos

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.0K
Author Spotlight: Emerging Technologies and Advanced Tools for Decoding Metabolomics Data Analysis
07:11

Author Spotlight: Emerging Technologies and Advanced Tools for Decoding Metabolomics Data Analysis

Published on: November 10, 2023

3.1K

Related Experiment Videos

Last Updated: Dec 23, 2025

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke
09:50

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke

Published on: February 12, 2015

11.5K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.0K
Author Spotlight: Emerging Technologies and Advanced Tools for Decoding Metabolomics Data Analysis
07:11

Author Spotlight: Emerging Technologies and Advanced Tools for Decoding Metabolomics Data Analysis

Published on: November 10, 2023

3.1K

Area of Science:

  • Biostatistics
  • Medical Informatics
  • Epidemiology

Background:

  • Network meta-analysis (NMA) is crucial for comparing multiple treatments.
  • Analyzing discrete multiple outcomes in NMA presents statistical challenges.
  • Existing methods may not fully capture the joint distribution of correlated discrete outcomes.

Purpose of the Study:

  • To propose a new Bayesian approach for network meta-analysis with discrete multiple outcomes.
  • To model the joint distribution of discrete outcomes using a Gaussian copula with binomial marginals.
  • To provide a flexible and robust framework for evidence synthesis.

Main Methods:

  • A Bayesian hierarchical random-effects model is employed.
  • Gaussian copula with binomial marginals models the joint distribution of outcomes.
  • An adaptive Markov Chain Monte Carlo (MCMC) algorithm facilitates posterior inference.
  • The model is implemented in the R package 'netcopula'.

Main Results:

  • The proposed Bayesian approach effectively handles discrete multiple outcomes in NMA.
  • Performance was assessed using two datasets from Cochrane reviews.
  • The method demonstrated comparable or improved performance against existing analyses.
  • The 'netcopula' R package provides a practical implementation.

Conclusions:

  • The novel Bayesian Gaussian copula model offers a powerful tool for network meta-analysis of discrete outcomes.
  • This approach improves the synthesis of evidence from multiple studies with complex outcome data.
  • The freely available 'netcopula' R package facilitates its application in biostatistical research.